Prevalence and Clinical Impact of Concomitant Mutations in Anaplastic Lymphoma Kinase Rearrangement Advanced Non-small-Cell Lung Cancer (Guangdong Association of Thoracic Oncology Study 1055)

Prevalence and Clinical Impact of Concomitant Mutations in Anaplastic Lymphoma Kinase Rearrangement Advanced Non-small-Cell Lung Cancer (Guangdong Association of Thoracic Oncology Study 1055)

Background: In patients with anaplastic lymphoma kinase (ALK) rearrangement-positive advanced non–small-cell lung cancer (NSCLC), ALK inhibitors are now the standard treatment, but their clinical efficacy varies widely for each patient. In this multicenter retrospective study, we evaluated the clini...

Full description

Bibliographic Details
Main Authors: Meichen Li, Xue Hou, Chengzhi Zhou, Weineng Feng, Guanming Jiang, Hao Long, Shuang Yang, Jing Chen, Na Wang, Kaicheng Wang, Likun Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Oncology
Subjects:
ALK rearrangement
non–small-cell lung cancer
concomitant mutations
crizotinib
next-generation sequencing
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01216/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.01216/full

Similar Items